Word: tumorous
(lookup in dictionary)
(lookup stats)
Dates: during 1970-1979
Sort By: most recent first
(reverse)
...patent any product of Folkman's research over the next 12 years. Harvard University and Monsanto negotiated the contract after Folkman sought to use the St. Louis firm's extensive tissue-culture equipment for work on his study of a large protein that, he hypothesizes, allows cancers to grow: Tumor Angiogenesis Factor...
Folkman published his findings slightly over one year ago, concluding that TAF is a protein that malignant tissue releases, instructing neighboring tissue to supply the budding tumor with a blood supply. Other pathologic conditions, as well as cancers, depend on the obedience of the victim in setting up an arterial supply to the lesion, or disease focus. What doctors speculate Monsanto is investing in is an agent or antibody that could block the action of the TAF protein. Such a pharmaceutical could be administered systematically upon diagnosis of a primary tumor, and the presence of the anti-TAF might insure...
...heart disease in its annual toll. Dr. Kurt J. Isselbacher, Mallinckrodt Professor of Medicine at Mass General Hospital, has an official interest in the academic acceptance of the field. He is chairman of Harvard's cancer committee and says, as does Frei, that the basic biology of the cancer tumor, and the subtle distinctions that make its cells malignant, are valid concerns for the basic scientist/pure academic...
...Samuel Hellman, Fuller American Cancer Society Professor of Radiation Therapy and chairman of the radiation therapy department, explains that the field is oriented more towards research than towards purely clinical considerations of dosages. "There's a tremendous amount of work being done on basic biology of tumor cells to make treatment more specific," he says. Radiation's effects on the DNA, or chemical genetic messenger system, of both malignant and normal cells, for instance, is an important area of basic cancer research, Hellman adds...
Tell that to Dr. Baruj Benacerraf, Fabyan Professor of Comparative Pathology, and he will shrug expansively. Benacerraf had been studying immunology, he says, "years before cancer became fashionable," and when the two fields overlapped, he had investigated the connection. Benacerraf's experiments with transplanting mouse tumors had indicated that tumor cells prompt immune defenses by the mouse. He says that some evidence suggests that the tumor might confuse the immune system's sense of what is self; that immune mechanisms begin to treat the malignant cells as "self" and then actually encourage growth of the tumor...